N/A
Completed N=52
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
Carcinoma, Renal Cell
Source: ClinicalTrials.gov NCT01056263 ↗
Enrolled (actual)
52
Serious AEs
—
Results posted
Mar 2012
Primary outcomePrimary: Overall Survival (OS) — 911.0 Days
Summary
The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 [NCT00076011] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival (OS) |
911.0 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects participating in this observational study originally participated in study A4061012 [NCT00076011] and may have also participated in study A4061008 [NCT00828919]
Exclusion Criteria
- Subjects who withdrew from the original study A4061012 [NCT00076011] or the continuing access study A4061008 [NCT00828919]
Data sourced from ClinicalTrials.gov (NCT01056263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.